Compare · RMD vs VVOS
RMD vs VVOS
Side-by-side comparison of ResMed Inc. (RMD) and Vivos Therapeutics Inc. (VVOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and VVOS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $33.83B, about 9167.1x VVOS ($3.7M).
- VVOS has been more active in the news (13 items in the past 4 weeks vs 6 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 1 for VVOS).
- Company
- ResMed Inc.
- Vivos Therapeutics Inc.
- Price
- -
- -
- Market cap
- $33.83B
- $3.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 6
- 13
- Recent ratings
- 25
- 1
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Vivos Therapeutics Inc.
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Latest RMD
- ResMed downgraded by Canaccord Genuity
- SEC Form 10-Q filed by ResMed Inc.
- SEC Form 8-K filed by ResMed Inc.
- Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
- Global General Counsel Rider Michael J sold $102,000 worth of ResMed Common Stock (400 units at $255.00) as part of a pre-agreed trading plan (SEC Form 4)
- Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.
- Chairman and CEO Farrell Michael J. sold $1,129,637 worth of ResMed Common Stock (4,991 units at $226.33) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
Latest VVOS
- SEC Form DEFA14A filed by Vivos Therapeutics Inc.
- SEC Form DEF 14A filed by Vivos Therapeutics Inc.
- SEC Form 4 filed by Vivos Therapeutics Inc.
- SEC Form 4 filed by Vivos Therapeutics Inc.
- SEC Form 4 filed by Vivos Therapeutics Inc.
- SEC Form PRER14A filed by Vivos Therapeutics Inc.
- SEC Form 8-K filed by Vivos Therapeutics Inc.
- Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
- SEC Form PRE 14A filed by Vivos Therapeutics Inc.
- Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel